All patients have now been enrolled in the mesothelioma phase Ib/II trial, where Oncos-102 is being evaluated in combination with standard of care (SoC) vs. SoC. Top-line results are now expected by year-end, which is somewhat ahead of the previous timeline (H1 2020). This is a welcome announcement that we believe should give a decent boost to the stock today.